| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0140-6736(03)13808-1 |
| P698 | PubMed publication ID | 12853201 |
| P2093 | author name string | Jayant A Talwalkar | |
| Keith D Lindor | |||
| P2860 | cites work | Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial | Q73330566 |
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation | Q73491973 | ||
| The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone | Q73574823 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| An exploratory population-based case-control study of primary biliary cirrhosis | Q73746110 | ||
| The pathology of primary biliary cirrhosis and autoimmune cholangitis | Q74280817 | ||
| Pruritus and fatigue in primary biliary cirrhosis | Q74280848 | ||
| Open-label trial of oral nalmefene therapy for the pruritus of cholestasis | Q74310569 | ||
| Fatigue in primary biliary cirrhosis | Q77586211 | ||
| Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study | Q77619532 | ||
| Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis | Q77647596 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial | Q78039888 | ||
| Cholestatic syndromes | Q79216771 | ||
| Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system | Q94054254 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis | Q31167633 | ||
| Anticentromere antibody in primary biliary cirrhosis | Q33553886 | ||
| Incidence of cancer in primary biliary cirrhosis: the Mayo experience | Q33601440 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Mitochondrial membrane perturbations in cholestasis. | Q33836633 | ||
| Primary biliary cirrhosis: an orchestrated immune response against epithelial cells | Q33916633 | ||
| PBC: an infectious disease? | Q34032141 | ||
| Effect of stanozolol on itching in primary biliary cirrhosis | Q34166986 | ||
| Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? | Q34190802 | ||
| Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization | Q34210591 | ||
| Primary biliary cirrhosis and primary sclerosing cholangitis | Q34210604 | ||
| Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype | Q34245122 | ||
| SEROLOGICAL TESTS IN DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS | Q34259351 | ||
| Fat-soluble vitamin levels in patients with primary biliary cirrhosis | Q34379099 | ||
| Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group | Q34408189 | ||
| Breast cancer in women with primary biliary cirrhosis | Q34491081 | ||
| Serum bilirubin: a prognostic factor in primary biliary cirrhosis | Q34494336 | ||
| Primary biliary cirrhosis: new thoughts on pathophysiology and treatment | Q34515652 | ||
| Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis | Q34516425 | ||
| Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease | Q34530672 | ||
| The association between gravidity and primary biliary cirrhosis | Q35143021 | ||
| Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment | Q35358467 | ||
| Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease | Q35359468 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis | Q35594898 | ||
| Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2 | Q35610980 | ||
| Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England | Q39452020 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? | Q71428839 | ||
| Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis | Q71605603 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes | Q72164376 | ||
| Antibodies to carbonic anhydrase in patients with immune cholangiopathies | Q72281881 | ||
| Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases | Q72313586 | ||
| Prediction of prognosis of primary biliary cirrhosis in Japan | Q72336290 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis | Q72582427 | ||
| Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis | Q72719827 | ||
| Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis | Q72736523 | ||
| Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial | Q73026352 | ||
| Is fatigue associated with cholestasis mediated by altered central neurotransmission? | Q73043135 | ||
| Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid | Q73122828 | ||
| The influence of smoking on vitamin D status and calcium metabolism | Q73282911 | ||
| Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis | Q73302312 | ||
| The geographical distribution of primary biliary cirrhosis in a well-defined cohort. | Q39587052 | ||
| Phenobarbital Effects in Cholestatic Liver Disease | Q39589574 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Familial primary biliary cirrhosis | Q40634968 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| Epidemiology and natural history of primary biliary cirrhosis in a US community | Q40735092 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 | ||
| Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis | Q42597329 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center | Q43513105 | ||
| Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future | Q43623767 | ||
| Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? | Q43676662 | ||
| Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis | Q43710194 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis | Q43967448 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Vitamin E deficiency and psychomotor dysfunction in adults with primary biliary cirrhosis | Q44412633 | ||
| The demography of primary biliary cirrhosis in Ontario, Canada | Q44439436 | ||
| When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? | Q44797408 | ||
| Natural history of pruritus in primary biliary cirrhosis | Q44797529 | ||
| Risk factors for primary biliary cirrhosis in a cohort of patients from the united states | Q44933098 | ||
| Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts. | Q45089631 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. | Q50623946 | ||
| Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. | Q50636830 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. | Q51597355 | ||
| Optimal timing of liver transplantation for primary biliary cirrhosis. | Q52240035 | ||
| Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. | Q52920374 | ||
| Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. | Q53662990 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis | Q58803462 | ||
| Molecular mimicry in liver disease | Q59072748 | ||
| Familial primary biliary cirrhosis reassessed: a geographically-based population study | Q61633902 | ||
| Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. | Q64974270 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Sodium fluoride prevents bone loss in primary biliary cirrhosis | Q67590482 | ||
| Immunomodulatory effects of ursodeoxycholic acid on immune responses | Q68225187 | ||
| A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis | Q68505504 | ||
| Sjögren's syndrome in patients with primary biliary cirrhosis | Q68802525 | ||
| Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens | Q68829231 | ||
| Pathogenesis of steatorrhea in primary biliary cirrhosis | Q68940388 | ||
| The Presentation and Diagnosis of 100 Patients with Primary Biliary Cirrhosis | Q69302463 | ||
| A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss | Q69721905 | ||
| Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival | Q69738156 | ||
| Primary biliary cirrhosis and Graves' disease | Q69805652 | ||
| Trial of penicillamine in advanced primary biliary cirrhosis | Q69887093 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group | Q70590270 | ||
| P433 | issue | 9377 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 53-61 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Primary biliary cirrhosis | |
| P478 | volume | 362 |
| Q37207972 | 38-year-old woman with abnormal liver enzymes and hyperlipidemia |
| Q33645189 | A case of primary biliary cirrhosis associated with pernicious anemia: a case report |
| Q33867374 | A case of primary biliary cirrhosis complicated by Behçet's disease and palmoplantar pustulosis |
| Q35837039 | A case of severe osteomalacia caused by Tubulointerstitial nephritis with Fanconi syndrome in asymptomotic primary biliary cirrhosis. |
| Q46872722 | AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers |
| Q46745228 | Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis |
| Q84476629 | American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis |
| Q36300105 | Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature |
| Q35926418 | Approach to a patient with elevated serum alkaline phosphatase |
| Q34993666 | Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease |
| Q33866371 | Autoimmune liver disease and the Canadian First Nations Aboriginal Communities of British Columbia's Pacific Northwest. |
| Q36166941 | B cell depletion in treating primary biliary cirrhosis: pros and cons |
| Q46484331 | B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid |
| Q35769888 | Can the laboratory affect the investigation and diagnosis of primary biliary cirrhosis? |
| Q54573681 | Chenodeoxycholic acid and taurochenodexycholic acid induce anti-apoptotic cIAP-1 expression in human hepatocytes. |
| Q24235780 | Chlorambucil for primary biliary cirrhosis |
| Q36567737 | Cholestatic liver disease. Recognizing the clinical signs |
| Q56907597 | Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome |
| Q37182934 | Clinical features and management of primary biliary cirrhosis. |
| Q55041843 | Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. |
| Q43114906 | Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis |
| Q37993224 | Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review |
| Q37194433 | Diagnosing and treating a patient with primary biliary cirrhosis |
| Q38266358 | Diagnosis and management of primary biliary cirrhosis |
| Q33612198 | Diagnostic utility of IgG and IgM immunohistochemistry in autoimmune liver disease |
| Q37699257 | Disappearance of Oral Lichen Planus After Liver Transplantation for Primary Biliary Cirrhosis and Immunosuppressive Therapy in a 63-year-Old Japanese Woman |
| Q45206678 | Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? |
| Q37245523 | Effect of asymmetric dimethylarginine (ADMA) on heart failure development |
| Q35674181 | Environmental pathways to autoimmune diseases: the cases of primary biliary cirrhosis and multiple sclerosis |
| Q36373258 | Enzyme inhibition assay for pyruvate dehydrogenase complex: clinical utility for the diagnosis of primary biliary cirrhosis |
| Q43457417 | Falls and fall-related injury are common in older people with chronic liver disease. |
| Q35249154 | Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis |
| Q55038191 | Frequency of monosomy X in women with primary biliary cirrhosis. |
| Q36119789 | From bases to basis: linking genetics to causation in primary biliary cirrhosis |
| Q48003560 | From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. |
| Q28268456 | Generalized morphea and primary biliary cirrhosis coexisting in a male patient |
| Q36202209 | Genes and (auto)immunity in primary biliary cirrhosis |
| Q37642274 | Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. |
| Q33795082 | Genetic Polymorphisms of Cytotoxic T-Lymphocyte Antigen 4 in Primary Biliary Cholangitis: A Meta-Analysis |
| Q47827554 | Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. |
| Q36667868 | Genomics and complex liver disease: Challenges and opportunities |
| Q48086460 | Geoepidemiology and space-time analysis of Primary biliary cirrhosis in Crete, Greece. |
| Q28235162 | Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis |
| Q35760984 | Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis |
| Q34012609 | Hyperhomocysteinemia and hypercoagulability in primary biliary cirrhosis. |
| Q38957567 | Imaging of autoimmune biliary disease |
| Q53019283 | Immunologic derangement preceding clinical autoimmunity. |
| Q40186249 | Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis |
| Q48529733 | Inflammatory myopathies associated with anti-mitochondrial antibodies |
| Q55044287 | Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. |
| Q38358951 | Intrahepatic gene expression profiles in chronic hepatitis B and autoimmune liver disease |
| Q43155895 | Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis? |
| Q37372660 | Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity |
| Q43419136 | Lack of PBC-specific antimitochondrial antibodies in patients with Chlamydia pneumoniae infection |
| Q53136628 | Lack of association between vitamin D receptor gene ApaI, BsmI, and TaqI polymorphisms and primary biliary cirrhosis risk: a meta-analysis. |
| Q80903284 | Liver biopsies from human females contain male hepatocytes in the absence of transplantation |
| Q42780223 | Liver physiology and liver diseases in the elderly |
| Q37527217 | Liver transplantation for primary biliary cirrhosis: results of aggressive corticosteroid withdrawal |
| Q34550505 | Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials |
| Q35811052 | Long-term prognosis after resection of cryptogenic hepatocellular carcinoma |
| Q36119464 | Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosis |
| Q46102659 | Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid |
| Q40086159 | Molecular diagnostics of primary biliary cirrhosis |
| Q26824664 | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis |
| Q42375647 | Novel strategies and therapeutic options for the management of primary biliary cholangitis |
| Q46940563 | Nuclear receptors, bile-acid detoxification, and cholestasis |
| Q38175055 | Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q51295484 | Ocular findings in patients with autoimmune liver disease. |
| Q37346015 | Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases |
| Q52727520 | Paracrine cellular senescence exacerbates biliary injury and impairs regeneration. |
| Q37681567 | Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid |
| Q50897074 | Phenomenology and emotional impact of neuropsychiatric symptoms in orthotopic liver transplant for hepatocellular carcinoma. |
| Q51636366 | Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid |
| Q82640100 | Polluting the pathogenesis of primary biliary cirrhosis |
| Q43719206 | Pregnancy and primary biliary cirrhosis: a case-control study |
| Q46078221 | Primary biliary cholangitis: a comprehensive overview |
| Q57141930 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q85213554 | Primary biliary cirrhosis |
| Q21202919 | Primary biliary cirrhosis |
| Q36740647 | Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature |
| Q34382057 | Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates |
| Q26992087 | Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis |
| Q36518882 | Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score |
| Q33164185 | Promoting self-management and adherence with strength and balance training for older people with long-term conditions: a mixed-methods study. |
| Q28078424 | Pulmonary Manifestations among Patients with Primary Biliary Cirrhosis |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q36822889 | Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis |
| Q37009925 | Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases |
| Q34462959 | Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients |
| Q50052185 | Scale development with small samples: a new application of longitudinal item response theory |
| Q37225962 | Secondary Sclerosing Cholangitis in Critically Ill Patients: Clinical Presentation, Cholangiographic Features, Natural History, and Outcome: A Series of 16 Cases |
| Q36065762 | Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman |
| Q45279427 | Small ubiquitin-related modifiers: A novel and independent class of autoantigens in primary biliary cirrhosis |
| Q81724962 | Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q45839711 | Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis |
| Q39515619 | T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. |
| Q44825320 | Tamoxifen in treatment of primary biliary cirrhosis |
| Q83403525 | The concept of hepatic artery-bile duct parallelism in the diagnosis of ductopenia in liver biopsy samples |
| Q36119459 | The enigma of primary biliary cirrhosis |
| Q47285348 | The impact of biopsychosocial factors on quality of life: women with primary biliary cirrhosis on waiting list and post liver transplantation |
| Q38622370 | The management of autoimmunity in patients with cholestatic liver diseases |
| Q34411295 | The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailinglist |
| Q38497377 | The soluble CTLA-4 receptor and its role in autoimmune diseases: an update |
| Q81008540 | The value of antinuclear antibodies in primary biliary cirrhosis |
| Q37469924 | Toll-like receptors as targets in chronic liver diseases |
| Q47971435 | Tubulointerstitial Nephritis with IgM-Positive Plasma Cells |
| Q37751552 | Tubulointerstitial nephritis and renal tubular acidosis of different types are rare but important complications of primary biliary cirrhosis |
| Q54854378 | Tubulointerstitial nephritis associated with primary biliary cirrhosis. |
| Q35588517 | Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory |
| Q36801651 | Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q24241945 | Ursodeoxycholic acid for primary biliary cirrhosis |
| Q52586105 | Vitamin D and the Liver-Correlation or Cause? |
| Q81320794 | [An experimental organ model for magnetic resonance imaging] |
| Q79320444 | [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?] |
Search more.